Definitions
Sorry, no definitions found. You may find more data at biogen's.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Biogen's.
Examples
-
Rituxan revenue from Biogen's joint venture with Roche Holding AG's Genentech Inc. unit, was roughly in line with the prior year at $258 million.
Biogen's Net Rises 25% as Company Invests in Pipeline Jon Kamp 2012
-
Sales of Biogen's flagship product Avonex, also an MS treatment, climbed about 8% to $703 million.
Biogen's Net Rises 25% as Company Invests in Pipeline Jon Kamp 2012
-
Overall volume in Biogen's options was the most in two weeks, Trade Alert data showed.
Traders Paint Abbot Labs, Biogen in Bullish Light Chris Dieterich 2011
-
More photos and interactive graphics Related Biogen's Net Rises 25% Both companies are counting on continued sales growth for drugs that still have patent protection to help soften the big patent losses.
Pfizer, Lilly Profits Fall as Drugs Lose Patents Peter Loftus 2012
-
Similar bullish sentiment showed up in Biogen's options, underpinned by a three-part trade involving puts and calls that expire in two months.
Traders Paint Abbot Labs, Biogen in Bullish Light Chris Dieterich 2011
-
Buying the $95 calls gives the investor exposure to gains in Biogen's stock, while selling options reduces the overall cost of the transaction and caps maximum potential profit.
Traders Paint Abbot Labs, Biogen in Bullish Light Chris Dieterich 2011
-
Biogen's BG-12 drug reduced MS flare-ups by a similar amount as Gilenya, but with fewer side effects.
Pills Offer Easier Way to Treat MS Thomas Gryta 2011
-
Biogen's stock rose Friday because the U.S. drug maker is developing a new orally administered MS drug that would compete with Gilenya.
EU Regulator Reviews Novartis MS Pill Sten Stovall 2012
-
Another drug, Biogen's Tysabri, was approved in 2004 but was later temporarily pulled from the market after it was linked to a rare brain infection.
Pills Offer Easier Way to Treat MS Thomas Gryta 2011
-
Biogen's most anticipated new product may be BG-12, an MS treatment candidate that can be taken as a pill rather than through injections, like most drugs approved today for the chronic and potentially disabling neurological disease.
Biogen's Net Rises 25% as Company Invests in Pipeline Jon Kamp 2012
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.